Adamis Pharmaceuticals (ADMP) Regains Compliance with NASDAQ Continued Listing Requirements

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) notifying the company that based on the company’s filing of its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021, June 30, 2021 and September 30, 2021, the company has regained compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission, and that the matter is now closed.

You May Also Be Interested In

• Longeveron (LGVN) Raises $11.4M in Gross Proceeds from Warrant Exercise Offering and Public Offering
• Intelligent Bio Solutions (INBS) Reports Prelim Q3 Results
• 22nd Century Group (XXII) Announces Resignation of Sullivan and Mish from Board